Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of medicine for preventing or treating fxr-mediated disease and its preparation method and application

A drug and disease technology, applied in the field of drugs for preventing or treating FXR-mediated diseases and its preparation and use, can solve the problems of low oral utilization and short half-life, and achieve improved oral utilization and half-life prolonged effect

Active Publication Date: 2017-06-06
BEIJING PRELUDE PHARM SCI & TECH
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But this medicine still has short half-life, the defect that oral utilization rate is not high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of medicine for preventing or treating fxr-mediated disease and its preparation method and application
  • A kind of medicine for preventing or treating fxr-mediated disease and its preparation method and application
  • A kind of medicine for preventing or treating fxr-mediated disease and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0042] The preparation of the compound shown in embodiment 1 formula (III)

[0043]

[0044] To a solution of compound 1 (2.5 g, 6.4 mmol) in methanol (60 mL) was added p-TsOH.H 2 O(p-toluenesulfonic acid monohydrate) (0.12 g, 0.64 mmol). The resulting mixture was stirred at room temperature for 3 hours. The solvent was evaporated under reduced pressure, and the residue was dissolved in EtOAc (ethyl acetate) (150 mL). NaHCO 3 (saturated, 100mL), water (50mL) and brine (50mL) washed twice, the organic layer was washed with Na 2 SO 4 Dried and evaporated under reduced pressure to obtain product 2 as a white solid (2.5 g, 96%).

[0045] 1 H NMR (400MHz, CDCl 3):δ3.66(s,3H),3.60(m,1H),2.85(dd,J=12.4,6.0Hz,1H),2.47-2.30(m,2H),2.28-2.20(m,2H), 2.05-1.60(m,10H),1.50-1.09(m,14H),0.92(d,3H),0.65(m,J=6.4Hz,3H).

[0046] To a solution of diisopropylamine (5.2 mL, 39.5 mmol) in dry tetrahydrofuran (30 mL) was added dropwise a solution of n-butyllithium (15.8 mL, 2.5M in n-he...

Embodiment 2

[0049] The preparation of embodiment 2 compound A

[0050]

[0051] To a solution of compound (III) (83 mg, 0.2 mmol) in MeOH (10 mL) was added TsOH (p-toluenesulfonic acid) (5.1 mg, 0.03 mmol). The mixture was stirred at room temperature for 16 hours. The solvent was evaporated under reduced pressure and the residue was dissolved in EtOAc (20ml), washed with saturated aqueous sodium bicarbonate (2x10ml), water (10ml) and brine (10ml). The organic layer was dried over anhydrous sodium sulfate and evaporated to dryness. The residue was purified by column chromatography on silica gel (eluted with DCM / MeOH (dichloromethane / methanol)=100:1 to 80:1) to obtain compound A as a white solid (42 mg, 50%).

[0052] 1 H NMR (400MHz, CDCl 3 ):3.70(s,1H),3.66(s,3H),3.43-3.37(m,1H),2.39-2.31(m,1H),2.26-2.18(m,1H),1.00(td,J=14.0 ,3.2Hz,1H),0.93-0.388(m,9H),0.66(s,3H).LC-MS: m / z 869.7[2M+H] + ,452.3[M+H 2 O] + .

Embodiment 3

[0053] The preparation of embodiment 3 compound B

[0054]

[0055] To a solution of compound (III) (83 mg, 0.2 mmol) in EtOH (10 mL) was added TsOH (5.1 mg, 0.03 mmol). The mixture was stirred at room temperature for 16 hours. The solvent was evaporated under reduced pressure, the residue was dissolved in EtOAc (20ml), washed with saturated aqueous sodium bicarbonate (2 x 10ml), water (10ml) and brine (10ml). The organic layer was dried over anhydrous sodium sulfate and evaporated to dryness. The residue was purified by column chromatography on silica gel (eluted with DCM / MeOH=100:1 to 80:1) to obtain compound B as a white solid (30 mg, 36%).

[0056] 1 H NMR (400MHz, CDCl 3 ):4.12(q,J=7.2Hz,2H),3.70(s,1H),3.43-3.35(m,1H),2.38-2.30(m,1H),2.26-2.18(m,1H),0.95- 0.86(m,12H),0.66(s,3H).LC-MS: m / z 897.7[2M+H] + ,466.4[M+H 2 O] + .

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicine for preventing or treating FXR-mediated diseases, and a preparation method and an application of the medicine. The medicine for preventing or treating FXR-mediated diseases has a structure shown in a formula I(I) in the specification, wherein R is CO(O)R' or P(O)(OH)2; and R' is C1-C6 alkyl. According to the compound provided by the invention, the half-life period is significantly prolonged; and the oral bioavailability is obviously improved.

Description

technical field [0001] The present invention relates to a medicine for preventing or treating FXR-mediated diseases, its preparation method and application. Background technique [0002] Farnesoid X receptor (FXR) is a member of the orphan nuclear receptor family. It was first cloned and discovered in rat liver cDNA library by Forman et al. in 1995. It is named because its transcriptional activity can be enhanced by supraphysiological concentrations of farnesoid. Northern and in situ analysis revealed that FXR is abundantly expressed in the lung, intestine, kidney, and adrenal gland. FXR forms a heterodimer with 9-cis retinoic acid receptor (RXR) and binds to DNA. The FXR / RXR heterodimer binds preferentially to a component consisting of binuclear receptor half-sites sharing the AG(G / T)TCA, which form inverted repeats and separate single nucleosides (IR-1 motif). However, these compounds fail to activate mouse and human FXR, making the nature of the endogenous FXR ligand un...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07J9/00C07J51/00A61K31/575A61K31/662A61P1/16A61P1/00A61P13/12A61P9/00A61P3/00A61P3/10A61P9/10A61P3/06
CPCC07J9/005
Inventor 王志岩
Owner BEIJING PRELUDE PHARM SCI & TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com